🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

212 results for “Bristol-Myers” Clear

  1. DEXAMETHASONE, DEXAMETHASONE, LENALIDOMIDE, Empliciti 400 mg powder for concentrate for solution for infusion., LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE

    Bristol-Myers Squibb / Pfizer EEIG

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  2. Dexamethason 4 mg JENAPHARM®, evorpacept, Isatuximab, Dexamethason 8 mg JENAPHARM®, Isatuximab

    Sanofi Pharma Bristol-Myers Squibb

    Cancer

    phase 2 small molecule active

    1 trial

  3. Dexamethason 8 mg JENAPHARM®, SAR445761 - belumosudil, Isatuximab, Isatuximab, Dexamethason 4 mg JENAPHARM®

    Sanofi Pharma Bristol-Myers Squibb

    Cancer

    phase 2 small molecule active

    1 trial

  4. FDC Nivolumab + Relatlimab + rHuPH20 Injection, Nivolumab/Relatlimab, OPDIVO 10 mg/mL concentrate for solution for infusion., Nivolumab Subcutaneous

    Bristol-Myers Squibb / Pfizer EEIG

    Melanoma

    phase 2 small molecule active

    1 trial

  5. Florquinitau F-18, Sodium Chloride, PRX005

    Bristol-Myers Squibb / Pfizer EEIG

    Early Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  6. Frexalimab, Matched Placebo for Test

    Sanofi Pharma Bristol-Myers Squibb

    Systemic lupus erythematosus

    phase 2 small molecule active

    1 trial

  7. Hexyon suspension for injection in pre-filled syringe Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)., MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, RotaTeq oral solution Rotavirus vaccine (live), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), MenPenta SD, Prevenar 13 suspension for in

    Sanofi Pharma Bristol-Myers Squibb

    Meningococcal immunization

    phase 2 small molecule active

    1 trial

  8. INBRX-101 Concentrate for Solution for Infusion 50mg/ml

    Sanofi Pharma Bristol-Myers Squibb

    Alpha-1 Antitrypsin Deficiency (AATD) Emphysema

    phase 2 small molecule active

    1 trial

  9. Imnovid 4 mg hard capsules, JAMP Pomalidomide, Pomalidomide Adalvo 3 mg hard capsules, Imnovid 1 mg hard capsules, Imnovid 4 mg hard capsules, Pomalidomide Adalvo 1 mg hard capsules, Imnovid 2 mg hard capsules, JAMP Pomalidomide, Imnovid 1 mg hard capsules, JAMP Pomalidomide, Dexamethason 4 mg JENAPHARM®, Imnovid 3 mg hard capsules, Pomalidomide Adalvo 4 mg hard capsules, Pomalidomide Adalvo 2 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Isatuximab, Isatuximab, JAMP Pomalidomide, Imnovid 3 mg hard capsul

    Sanofi Pharma Bristol-Myers Squibb

    Cancer

    phase 2 small molecule active

    1 trial

  10. Isatuximab, Dexamethason 8 mg JENAPHARM®, Dexamethason 4 mg JENAPHARM®, Isatuximab

    Sanofi Pharma Bristol-Myers Squibb

    Cancer

    phase 2 small molecule active

    1 trial

  11. Isatuximab, Kyprolis 60 mg powder for solution for infusion, METHYLPREDNISOLONE , MONTELUKAST , DexaGalen® 8 mg injekt Injektionslösung, DIPHENHYDRAMINE , Dexamethason 4 mg JENAPHARM®, Dr. Reddy's Carfilzomib, PARACETAMOL

    Sanofi Pharma Bristol-Myers Squibb

    Cancer - Relapsed/refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  12. Itepekimab

    Sanofi Pharma Bristol-Myers Squibb

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule active

    1 trial

  13. Itepekimab, Matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Bronchiectasis

    phase 2 small molecule active

    1 trial

  14. MRTX1719

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. Match Placebo to Test Product, SAR441566, SAR441566

    Sanofi Pharma Bristol-Myers Squibb

    Psoriasis

    phase 2 small molecule active

    1 trial

  16. Match placebo to test product, Balinatunfib

    Sanofi Pharma Bristol-Myers Squibb

    Crohn's disease

    phase 2 small molecule active

    1 trial

  17. Match placebo to test product, METHOTREXATE , SAR441566, SAR441566

    Sanofi Pharma Bristol-Myers Squibb

    Rheumatoid arthritis

    phase 2 small molecule active

    1 trial

  18. Matched Placebo for test product Frexalimab, Frexalimab

    Sanofi Pharma Bristol-Myers Squibb

    Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  19. Matched placebo for product, GADOBUTROL , SAR443820

    Sanofi Pharma Bristol-Myers Squibb

    Multiple sclerosis

    phase 2 small molecule active

    1 trial

  20. Matched placebo for test product, Itepekimab

    Sanofi Pharma Bristol-Myers Squibb

    Respiratory tract diseases

    phase 2 small molecule active

    1 trial

  21. Matched placebo for test product, SAR444336

    Sanofi Pharma Bristol-Myers Squibb

    Digestive system diseases

    phase 2 small molecule active

    1 trial

  22. Matched, SAR444656

    Sanofi Pharma Bristol-Myers Squibb

    Dermatitis atopic

    phase 2 small molecule active

    1 trial

  23. Matching Placebo for Test, SAR443765 / LUNSEKIMIG

    Sanofi Pharma Bristol-Myers Squibb

    Asthma

    phase 2 small molecule active

    1 trial

  24. NANOBODY® Placebo; The placebo is a standard placebo formulation containing common excipients for NANOBODY drug products and is used by Sanofi for NANOBODY clinical studies., SAR442970

    Sanofi Pharma Bristol-Myers Squibb

    Crohn’s disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources